Genome‐scale CRISPR–Cas9 screen identifies PAICS as a therapeutic target for EGFR wild‐type non‐small cell lung cancer

Abstract Epidermal growth factor receptor‐targeted (EGFR‐targeted) therapies show promise for non‐small cell lung cancer (NSCLC), but they are ineffective in a third of patients who lack EGFR mutations. This underlines the need for personalized treatments for patients with EGFR wild‐type NSCLC. A ge...

Full description

Bibliographic Details

Published in:	MedComm
Main Authors:	Yufeng Li, Lingyun Zhu, Jiaqi Mao, Hongrui Zheng, Ziyi Hu, Suisui Yang, Tianyu Mao, Tingting Zhou, Pingping Cao, Hongshuai Wu, Xuerong Wang, Jing Wang, Fan Lin, Hua Shen
Format:	Article
Language:	English
Published:	Wiley 2024-03-01
Subjects:	cell cycle DNA damage EGFR wild‐type NSCLC PAICS
Online Access:	https://doi.org/10.1002/mco2.483